Last 10 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.11 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 241.66 | 901.15 | 303.90 | 5.02 | 18.86 | 964.96 | 1594.52 | — | — | — | — |
| — | -6.6% | -80.9% | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.12 | 0.91 | 0.72 | 0.31 | 0.94 | 1.21 | 8.84 | — | — | — | — |
| — | -25.1% | -91.9% | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Virax Biolabs Group Limited's operating margin was -238316.8% in Q4 2025, down 180192.6 pp QoQ and down 85079.1 pp YoY. This marks the 4th consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of -76180.3% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 6286.2% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -838.2% | -3381.2% | -130.7% | 50.1% | 13.7% | -52.9% | 2.0% | 207.6% | — | -21.3% | 45.8% |
| — | -6286.2% | -6480.4% | -75.8% | — | -148.1% | -95.5% | — | — | — | — | |
| Operating Margin | -97344.8% | -238316.8% | -58124.2% | -4742.6% | -3537.5% | -153237.8% | -25010.1% | 1256.6% | — | -248.7% | -652.1% |
| — | -55.5% | -132.4% | -477.4% | — | -61525.1% | -3735.6% | — | — | — | — | |
| Net Margin | -95739.2% | -239827.3% | -55651.7% | -4784.7% | -3803.5% | -143301.8% | -25062.7% | 1245.3% | — | -280.0% | -708.9% |
| — | -67.4% | -122.0% | -484.2% | — | -51074.1% | -3435.7% | — | — | — | — |
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -114.4% | -47.6% | -40.7% | -68.0% | -38.8% | -61.5% | -97.6% | — | — | — | — |
| — | +22.5% | +58.3% | — | — | — | — | — | — | — | — | |
| ROA | -101.8% | -41.6% | -36.9% | -61.1% | -34.6% | -53.1% | -54.0% | -1581.6% | -576.5% | -616.5% | -3131.4% |
| — | +21.6% | +31.6% | +96.1% | +94.0% | +91.4% | +98.3% | — | — | — | — | |
| ROIC | -273.2% | -147.3% | -123.1% | -192.5% | -462.5% | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 31.5% YoY to 7.27x, tightening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.07 | 0.04 | 0.03 | 0.02 | 0.00 | — | — | — | — |
| — | +320.2% | +7827.7% | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.27 | 7.27 | 11.58 | 25.94 | 7.59 | 10.61 | 4.64 | 0.04 | 0.04 | 0.05 | 0.02 |
| — | -31.5% | +149.6% | +66233.8% | +18337.5% | +23226.1% | +25290.0% | — | — | — | — | |
| Quick Ratio | 7.13 | 7.13 | 11.20 | 25.58 | 7.56 | 10.58 | 4.64 | 0.02 | 0.02 | 0.02 | 0.02 |
| — | -32.6% | +141.5% | +114699.5% | +35883.9% | +49599.0% | +25290.0% | — | — | — | — | |
| Interest Coverage | -105.93 | -100.77 | -112.50 | -226.09 | -267.57 | -732.46 | -149.94 | -901.81 | -40.07 | -25.97 | -7.18 |
| — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 10 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonVirax Biolabs Group Limited's current P/E is -0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Virax Biolabs Group Limited's current operating margin is -97344.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Virax Biolabs Group Limited's business trajectory between earnings reports.